Warner-lambert Company

Other

Cocensys Inc.

Jonathan L Wright

Lawrence D Wise

Dennis M Downing

Nancy C Lan

Stephen J Johnson

Sui Xiong Cai

Eckard Weber

David Juergen Wustrow

Juan C Jaen

Bradley W Caprathe

Christopher Franklin Bigge

Shelly Ann Glase

Suzanne Ross Kesten

Zhang-Lin Zhou

Richard Woodward

William J Smith, Iii

John F Keana

Ravindra B Upasani

John Fw Keana

Duane Hartwell

A trailered brake workstation mounts on the horizontal frame of a two-wheeled trailer, a pair of longitudinally-spaced transverse horizontal guide bars at an elevated position above the frame. The guide bars mount slides which are secured to the bottom of a longitudinally-disposed brake. Thus the brake, via the slides, can be shifted laterally on the horizontal guide bars between an internal or centered position it which it may be locked for hauling and storing, and a side position in which it may be locked and available for operative use. A box and a cover protect the brake in the internal or centered position from the elements. A work table may also be transported, being stored in the throat of the brake during transportation, and disposed for use on the other side of the trailer when the brake is operative.

Trailered brake workstation

Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using the 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as cerebral ischemia, central nervous system trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headaches, convulsions, aminoglycoside antibiotics-induced hearing loss, chronic pain, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, urinary incontinence and neurodegenerative disorders such as lathyrism, Alzheimers' Disease, Parkinsonism, and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

Novel 4-Benzyl piperidine alkylsulfoxide heterocycles are disclosed and their use as subtype selective NMDA receptor antagonists, particularly for the treatment of Parkinson's disease, most preferably in combination with L-DOPA.

4-Benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists

4-substituted piperidine analogs and their use as subtype selective NMDA

Sulfonylquinolines are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antiobesity agents and for the treatment of hypertension.

Sulfonylquinolines as central nervous system and cardiovascular agents

Benzimidazoles and imidazopyridines are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotis depression, substance abuse, and compulsive disorders.

Benzimidazoles and imidazopyridines as central nervous system agents

Dimeric benzimidazoles are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders.

Dimeric benzimidazoles as central nervous system agents

1,3-Substituted cycloalkenes and cycloalkanes are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as dopaminergic, antipsychotic, and antihypertensive agents as well as for treating hyperprolactinaemia-related conditions and central nervous system disorders.

1,3-substituted cycloalkenes and cycloalkanes as central nervous system

Naphthalamides are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful as central nervous system agents and are particularly useful as antipsychotic agents and as agents for the treatment of disorders which respond to dopaminergic blockade including psychotic depression, substance abuse, and compulsive disorders.

Naphthalamides as central nervous system agents

Growing community of inventors

Ann Arbor, MI, United States of America

Jonathan L Wright